Fmc- Lexington South Dialysis is a medicare approved dialysis facility center in Lexington, Kentucky and it has 16 dialysis stations. It is located in Fayette county at 171 N Eagle Creek Dr Ste 110, Lexington, KY, 40509. You can reach out to the office of Fmc- Lexington South Dialysis at (859) 264-7775. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Fmc- Lexington South Dialysis has the following ownership type - Profit. It was first certified by medicare in June, 2002. The medicare id for this facility is 182556 and it accepts patients under medicare ESRD program.
Name | Fmc- Lexington South Dialysis |
---|---|
Location | 171 N Eagle Creek Dr Ste 110, Lexington, Kentucky |
No. of Dialysis Stations | 16 |
Medicare ID | 182556 |
Managed By | Fresenius Medical Care |
Ownership Type | Profit |
Late Shifts | No |
171 N Eagle Creek Dr Ste 110, Lexington, Kentucky, 40509 | |
(859) 264-7775 | |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
NPI Number | 1891807616 |
Organization Name | Rcg Lexington South |
Doing Business As | Rcg University Division, Inc. |
Address | 171 N Eagle Creek Dr Lexington, Kentucky, 40509 |
Phone Number | (859) 264-7775 |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 67% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 10% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 23% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 65% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 14% |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 66% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 15% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 19% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 76% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 19% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 5% | 12% |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 83% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 17% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 76% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 3% | 12% |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
Dialysis patients with Hemoglobin data | 41 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 15 |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 78 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 621 |
Percentage of adult patients getting regular hemodialysis at the center | 96 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Fmc- Lexington South Dialysis with elevated calcium levels.
Patients with hypercalcemia | 85 |
Hypercalcemia patient months | 673 |
Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
Patients with Serumphosphor | 91 |
Patients with Serumphosphor less than 3.5 mg/dL | 7 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 19 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 26 |
Patients with Serumphosphor greater than 7 mg/dL | 21 |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 73 |
Patient months included in arterial venous fistula and catheter summaries | 503 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 46 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 13 |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 71 |
Hospitalization Rate in facility | 166.2 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 302.5 |
Hospitalization Rate: Lower Confidence Limit | 94.4 |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Fmc- Lexington South Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 22 (As Expected) |
Readmission Rate: Upper Confidence Limit | 32.1 |
Readmission Rate: Lower Confidence Limit | 13.6 |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Fmc- Lexington South Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .38 (As Expected) |
SIR: Upper Confidence Limit | 1.26 |
SIR: Lower Confidence Limit | .06 |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Fmc- Lexington South Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 59 |
Transfusion Rate in facility | 58.4 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 134.4 |
Transfusion Rate: Lower Confidence Limit | 28.1 |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Fmc- Lexington South Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 399 |
Mortality Rate in facility | 22 (As Expected) |
Mortality Rate: Upper Confidence Limit | 28.5 |
Mortality Rate: Lower Confidence Limit | 16.7 |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago
Kentucky Childrens Hospital Location: 800 Rose Street, Mn-109, Lexington, Kentucky, 40536 Phone: (859) 323-8965 |
DCI - South Lexington Location: 2374 Professional Heights Dr., Lexington, Kentucky, 40503 Phone: (859) 967-0400 |
Fmc- Lexington South Dialysis Location: 171 N Eagle Creek Dr Ste 110, Lexington, Kentucky, 40509 Phone: (859) 264-7775 |
FMC - Kentucky Renal Care Group - Lexington East Location: 1101 Winchester Rd., Suite 100, Lexington, Kentucky, 40505 Phone: (859) 225-4922 |
News Archive
Nearly three-quarters of healthcare executives surveyed earlier this month say healthcare reform will have a negative financial impact on their facilities, while more than 60 percent note that reform will have a somewhat or very detrimental effect on the quality of care their facilities are able to provide.
Novo Solutions MD announces the launch of NovoScarMD the most scientifically advanced scar cream to come to market in 10 years. NovoScarMD reverses existing and new scar damage, keloids, and stretch marks, and rapidly returns skin to its original state with almost no trace of skin injury
The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.
Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.
Italian researchers report that liver transplant candidates who have a strong religious connection have better post-transplant survival. This study also finds that religiosity—regardless of cause of death—prolongs the life span of individuals who underwent liver transplantation.
› Verified 4 days ago